Top Brass Makes Big Moves as Cartesian Therapeutics Executives Cash In on Shares

New insider activity at Cartesian Therapeutics ( (RNAC) ) has taken place on January 8, 2026.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Recent insider activity at Cartesian Therapeutics shows significant stock sales by top executives. President & CEO Carsten Brunn sold 23,766 shares of company stock for a total of $161,846. Chief Financial Officer Blaine Davis disposed of 10,591 shares, generating proceeds of $72,124. In addition, Chief Medical Officer Milos Miljkovic sold 3,573 shares, with the transaction valued at $24,332. These combined insider sales highlight notable share disposals across the company’s senior leadership team. Recent Updates on RNAC stock In the last 24 hours, the key development for Cartesian Therapeutics (RNAC) was the announcement of inducement stock option grants to two new employees, totaling 7,350 shares at an exercise price aligned with the prior Nasdaq closing price. This move, made under the company’s inducement incentive plan and Nasdaq rules, signals ongoing investment in talent to support its strategic and clinical initiatives but does not itself indicate a direct change in analyst price targets or reflect new earnings or clinical data. The article references prior analyst commentary that has tied rating and target adjustments primarily to Cartesian’s strategic repositioning, promising clinical data, and perceived share mispricing relative to its therapeutic profile and realignment efforts, but no new target changes or fresh underlying reasons for such changes are disclosed in the covered 24-hour period. Spark’s Take on RNAC Stock According to Spark, TipRanks’ AI Analyst, RNAC is a Neutral. The score is held down primarily by weak financial performance (ongoing losses, negative gross margin, and negative equity) and bearish technicals (price below key moving averages and negative MACD). Positive corporate updates (encouraging clinical data and a finance leadership hire) provide some offset, but valuation metrics offer limited support due to a non-meaningful negative P/E and no dividend yield. To see Spark’s full report on RNAC stock, click here. More about Cartesian Therapeutics YTD Price Performance: 7.63% Average Trading Volume: 176,793 Technical Sentiment Signal: Sell Current Market Cap: $183.1M